What is SCTX's market cap?

$292.87M, based on the Nov 2 close of $15.47.

How much of SCTX is sold short?

1.1M shares, 14.6% of float, as of Oct 15, 2026.

What sector is SCTX in?

Healthcare, in the Biotechnology industry.

NASDAQ · SCTXHealthcareBiotechnology

Scribe Therapeutics Inc. Common Stock (SCTX)

$15.47+0.32%

Close Nov 2, 2026 · split-adjusted

Oct 30, 2026$15.42▼ 48.15% in range

Sep 11, 2026Low $15.40 · High $33.00Oct 30, 2026

What changed · written from our data

As of Nov 2, 2026

Scribe Therapeutics closed at $15.47 on Nov 2, up 0.32%, within 0.4% of its lowest close since Sep 11. Volume of 214.8K shares was 0.49× its 20-day average (below normal).

Split-adjusted performance: -7.9% over one month.

Short interest was 1.1M shares at the Oct 15 settlement, down 54.7% from the prior report (14.6% of float, 2.4 days to cover).

Market cap$292.9M18.9M shares

Revenue · quarter——

Diluted EPS——

P/E · TTM—

Net margin—

Dividend yieldNone

Range since Sep 1115.40 – 33.00−53.1% from high

Volume214.8K0.49× 20-day avg

Volatility · 60d—Annualised

Short % of float14.6%2.4 days to cover

Net cash—

Next earnings—Not scheduled

Split-adjusted performance

1W −0.8%1M −7.9%3M —6M —YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size54

Industry medians: 6-month return −22.7%, revenue growth +8.4%, net margin −271.3%, P/E 20.4×.

Short interest

Details →

Shares short1.1M−54.7% vs prior

Days to cover2.4Settled Oct 15

% of float14.6%

Short vol. 10d76.5%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
SCTXScribe Therapeutics	$15.47	+0.32%	—	—	—	—	$292.9M
EIKNEikon Therapeutics	$5.42	+2.07%	−47.2%	—	—	—	$293.6M	Compare
AGENAgenus	$6.54	−4.46%	+62.6%	+34.4%	−1.7%	3.2	$295.1M	Compare
SABSSAB Biotherapeutics	$3.32	−0.90%	−10.0%	—	—	—	$302.1M	Compare
IPSCCentury Therapeutics	$1.50	+2.04%	−34.5%	—	—	—	$271.6M	Compare
KYTXKyverna Therapeutics	$5.20	−8.38%	−42.3%	—	—	—	$321.3M	Compare
XFORX4 Pharmaceuticals	$3.30	−1.64%	−21.7%	+346.3%	−183.5%	—	$326.7M	Compare
SRZNSurrozen	$28.54	−1.72%	−11.0%	+408.6%	640.8%	—	$335.4M	Compare
LCTXLineage Cell Therapeutics	$1.00	0.00%	−29.6%	−61.3%	138.6%	—	$252.9M	Compare

News about Scribe Therapeutics

All news →

No recent articles focused on Scribe Therapeutics.

Quick answers

What does Scribe Therapeutics do?: Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD).
What is SCTX's market cap?: $292.87M, based on the Nov 2 close of $15.47.
How much of SCTX is sold short?: 1.1M shares, 14.6% of float, as of Oct 15, 2026.
What sector is SCTX in?: Healthcare, in the Biotechnology industry.

About Scribe Therapeutics

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.

HQ: Alameda, CAListed Jul 24, 2026scribetx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology